Cathelicidin (LL-37) vs Defensin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
LL-37 is the sole human cathelicidin antimicrobial peptide, derived by proteolytic cleavage of the 18 kDa precursor hCAP18 (encoded by the CAMP gene). It is produced by neutrophils, epithelial cells of the skin, gut, and airways, and mast cells....
Calculate Cathelicidin (LL-37) dose →Defensins are a superfamily of small, cysteine-rich cationic antimicrobial peptides that form a critical component of innate immunity across virtually all multicellular organisms. In humans, alpha-defensins (HNP-1 to -4 in neutrophils; HD-5, HD-6 in intestinal Paneth cells) and b...
Calculate Defensin dose →| Parameter | Cathelicidin (LL-37) | Defensin |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Clinical Research | Research/Therapeutic Development |
| Half-Life | < 10 min (plasma) | Minutes-hours (tissue dependent) |
| Typical Dose | Research: 1-100 ug/mL (topical) | Research only |
| Frequency | Varies by application | N/A |
| Route | Endogenous; topical/inhalation (research) | Endogenous; topical/intranasal (research) |
| FDA Status | No approval (clinical trials ongoing) | No approval (research stage) |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.